Safety and feasibility of fasting in combination with platinum-based chemotherapy
Tanya B Dorff, Susan Groshen, Agustin Garcia, Manali Shah, Denice Tsao-Wei, Huyen Pham, Chia-Wei Cheng, Sebastian Brandhorst, Pinchas Cohen, Min Wei, Valter Longo, David I Quinn, Tanya B Dorff, Susan Groshen, Agustin Garcia, Manali Shah, Denice Tsao-Wei, Huyen Pham, Chia-Wei Cheng, Sebastian Brandhorst, Pinchas Cohen, Min Wei, Valter Longo, David I Quinn
Abstract
Background: Short-term starvation prior to chemotherapy administration protects mice against toxicity. We undertook dose-escalation of fasting prior to platinum-based chemotherapy to determine safety and feasibility in cancer patients.
Methods: 3 cohorts fasted before chemotherapy for 24, 48 and 72 h (divided as 48 pre-chemo and 24 post-chemo) and recorded all calories consumed. Feasibility was defined as ≥ 3/6 subjects in each cohort consuming ≤ 200 kcal per 24 h during the fast period without excess toxicity. Oxidative stress was evaluated in leukocytes using the COMET assay. Insulin, glucose, ketones, insulin-like growth factor-1 (IGF-1) and IGF binding proteins (IGFBPs) were measured as biomarkers of the fasting state.
Results: The median age of our 20 subjects was 61, and 85 % were women. Feasibility criteria were met. Fasting-related toxicities were limited to ≤ grade 2, most commonly fatigue, headache, and dizziness. The COMET assay indicated reduced DNA damage in leukocytes from subjects who fasted for ≥48 h (p = 0.08). There was a non-significant trend toward less grade 3 or 4 neutropenia in the 48 and 72 h cohorts compared to 24 h cohort (p = 0.17). IGF-1 levels decreased by 30, 33 and 8 % in the 24, 48 and 72 h fasting cohorts respectively after the first fasting period.
Conclusion: Fasting for 72 h around chemotherapy administration is safe and feasible for cancer patients. Biomarkers such as IGF-1 may facilitate assessment of differences in chemotherapy toxicity in subgroups achieving the physiologic fasting state. An onging randomized trial is studying the effect of 72 h of fasting.
Trial registration: NCT00936364 , registered propectively on July 9, 2009.
Keywords: Chemotherapy; Fasting; Insulin-like growth factor; Neutropenia; Oxidative stress.
Figures
References
- Appenroth D, Frob S, Kersten L, et al. Protective effects of vitamin E and C on cisplatin nephrotoxicity in developing rats. Arch Toxicol. 1997;71:677–83. doi: 10.1007/s002040050444.
- DeMartinis BS, Bianchi MD. Effect of vitamin C supplementation against cisplatin-induced toxicity and oxidative DNA damage in rats. Pharmacol Res. 2001;44:317–20. doi: 10.1006/phrs.2001.0860.
- Yuce A, Atessahin A, Ceribasi AO, Aksakal M. Ellagic acid prevents cisplatin induced oxidative stress in liver and heart tissue of rats. Basic Clin Pharm Toxicol. 2007;101:345–9. doi: 10.1111/j.1742-7843.2007.00129.x.
- Block KI, Koch AC, Mead MN, Tothy PK, Newman RA, Gyllenhaal C. Impact of antioxidant supplementation on chemotherapeutic toxicity: a systematic review of the evidence from randomized controlled trials. Int J Cancer. 2008;123:1227–39. doi: 10.1002/ijc.23754.
- Raffaghello L, Lee C, Safdie FM, et al. Starvation-dependent differential stress resistance protects normal but not cancer cells against high-dose chemotherapy. Proc Natl Acad Sci. 2008;105:8215-20.
- Csizsar A, Labinskyy N, Jimenez R, et al. Anti-oxidative and anti-inflammatory vasoprotective effects of caloric restriction in aging: role of circulating factors and SIRT-1. Mech Age Develop. 2009;130:518–27. doi: 10.1016/j.mad.2009.06.004.
- Lee C, Raffaghello L, Brandhorst S, et al. Fasting cycles retard growth of tumors and sensitize a range of cancer cell types to chemotherapy. Sci Transl Med. 2012;4:124–7. doi: 10.1126/scitranslmed.3003293.
- Mansell PI, Macdonald IA. The effect of starvation on insulin-induced glucose disposal and thermogenesis in humans. Metabolism. 1990;39:502–10. doi: 10.1016/0026-0495(90)90009-2.
- Romijin JA, Godfried MH, Hommes MJT, et al. Decreased glucose oxidation during short-term starvation. Metabolism. 1990;39:525–30. doi: 10.1016/0026-0495(90)90012-2.
- NgoTH BRJ, Tymchuk CN, et al. Effect of diet and exercise on serum insulin, IGF-1, and IGFBP-1 levels and growth of LNCaP Cells in Vitro. Cancer Causes Control. 2002;13:929–35. doi: 10.1023/A:1021911517010.
- O’Sullivan U, Gluckman PD, Breier BH, et al. Insulin-like growth factor-1 (IGF-1) in mice reduces weight loss during starvation. Endocrinology. 1989;125:2793–4. doi: 10.1210/endo-125-5-2793.
- Muzumdar RH, Ma X, Fishman S, Yang X, Atzmon G, et al. Central and opposing effects of IGF-1 and IGF-binding protein-3 on systemic insulin action. Diabetes. 2006;55:2788–96. doi: 10.2337/db06-0318.
- Milman S, Atzmon G, Huffman DM, Wan J, Crandall JP, et al. Low insulin-like growth factor-1 level predicts survival in humans with exceptional longevity. Aging Cell. 2014;13:769–71. doi: 10.1111/acel.12213.
- Ostling O, Johanson KJ. Biochem Biophys Res Commun. 1984;123:291–8. doi: 10.1016/0006-291X(84)90411-X.
- Olive PL, Wlodek D, Durand RE, Banath JP. Factors influencing DNA migration from individual cells subjected to gel electrophoresis. Exp Cell Res. 1992;198:259–67. doi: 10.1016/0014-4827(92)90378-L.
- Everitt AV, LeCouteur DG. Life extension by calorie restriction in humans. Ann NY Acad Sci. 2007;1114:428–33. doi: 10.1196/annals.1396.005.
- Dunn SE, Ehrlich M, Sharp NJH, et al. A dominant negative mutant of the insulin-like growth factor-1 receptor inhibits the adhesion, invasion and metastasis of breast cancer. Cancer Res. 1998;58:3353–61.
- Kritchevsky D. Diet and cancer: what’s next? J Nutr. 2003;133:3827S–9.
- Lee C, Safdie FM, Raffaghello L, et al. Reduced levels of IGF-1 mediate differential protection of normal and cancer cells in response to fasting and improve chemotherapeutic index. Cancer Res. 2010;70:1564–72. doi: 10.1158/0008-5472.CAN-09-3228.
- Rock CL, Demark-Wahnefried W. Nutrition and survival after the diagnosis of breast cancer: a review of the evidence. J Clin Oncol. 2002;20:3302–16. doi: 10.1200/JCO.2002.03.008.
- Chan JM, Gann PH, Giovannucci GL. Role of diet in prostate cancer development and progression. J Clin Oncol. 2005;23:8152–60. doi: 10.1200/JCO.2005.03.1492.
- Kjeldsen-Kragh J, Borchgrevink CF, Laerum E, et al. Controlled trial of fasting and one-year vegetarian diet in rheumatoid arthritis. Lancet. 1991;338:899–902. doi: 10.1016/0140-6736(91)91770-U.
- Varady KA, Hellerstein MK. Alternate day fasting and chronic disease prevention: a review of human and animal trials. Am J Clin Nutr. 2007;86:7–13.
- Weindruch R, Sohal RS. Caloric intake and aging. New Engl J Med. 1997;337:986–94. doi: 10.1056/NEJM199710023371407.
- Ngo TH, Barnard RJ, Anton T, Tran C, Elashoff D, Heber D, et al. Effect of isocaloric low-fat diet on prostate cancer xenograft progression to androgen independence. Cancer Res. 2004;64:1252. doi: 10.1158/0008-5472.CAN-03-3830.
- Smith WJ, Underwood LE, Clemmons DR. Effects of caloric or protein restriction on insulin-like growth factor-1 (IGF-1) and IGF-binding protein in children and adults. J Clin Endocrinol Metab. 1995;80:443–9.
- Cheng C-W, Adams GB, Perin L, et al. Prolonged fasting reduces IGF-1/PKA to promote hematopoietic stem cell-based regeneration and reverse immunosuppression. Cell Stem Cell. 2014;14:810–23. doi: 10.1016/j.stem.2014.04.014.
Source: PubMed